Monthly Prescribing Reference

Aflibercept Shows Clinical Activity for Malignant Ascites

HealthDay News— Aflibercept, a potent inhibitor of vascular endothelial growth factor (VEGF), shows clinical activity and increases the time to repeat paracentesis for patients with advanced ...
The Globe and Mail

Malignant Ascites Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Clover Biopharmaceuticals

DelveInsight’s, “Malignant Ascites Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the ...
Medscape

Catumaxomab Effective in Treating Malignant Ascites

August 31, 2010 (Shenzhen, China) — Catumaxomab (Removab, Fresenius Biotech) is the first causal therapy against malignant ascites that has the approval of the European Commission. A phase 1/2 trial ...
Business Wire

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature ...
Business Wire

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...
MedPage Today

Cancer Ascites Responds to Outpatient Tx

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window TAMPA, Fla. -- ...
Healio

Despite reduced malignant ascites in ovarian cancer, aflibercept should be used with caution

Please provide your email address to receive an email when new articles are posted on . Final results of a phase 2 study indicated that the use of the VEGF-targeting aflibercept significantly reduced ...
Nasdaq

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using ...
The Globe and Mail

LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE ...
Mena FN

Malignant Ascites Market Forecasted To Surge In Coming Years, 2024-2034 Analysis By Delveinsight

DelveInsight's Malignant Ascites Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NEVADA, UNITED STATES, July 2, 2024 /EINPresswire / -- ...
PharmiWeb

Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites

MUNICH, GERMANY, AND BASILDON, UK / ACCESS Newswire / February 13, 2025 / LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an ...